Access Safety and Efficacy Post Endovascular Intervention

Status unconfirmed · Not applicable

Conditions studied: Cardiovascular Disease.

In brief

The goal of this study is to assess the safety and effectiveness of the AXERA Access System in subjects undergoing Common Femoral Artery (CFA) access for Percutaneous Coronary Intervention (PCI) and/or Peripheral Vascular Intervention (PVI) through a 5 French (F) or 6F introducer sheath.

Key facts

Study ID

NCT01773148

Run by

Arstasis, Inc.

People needed

240

Starts

2012-12-01

Expected to finish

2015-06-01

Last updated by the study team

2015-02-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is 18 years of age or older.
• Subject is clinically indicated for a PCI or PVI involving access through a 5F or 6F introducer sheath in the femoral artery.
• Subject is able to ambulate without assistance prior to the procedure and can be expected to ambulate (20 feet) within 2 hours post procedure.
• Female subjects of child bearing potential must have a negative pregnancy test.

You may not qualify if…

• Subjects who are pregnant or lactating.
• Subject has a pre-existing severe non-cardiac systemic disease/illness or another reason that results in a projected life expectancy of less than 1 year.
• Subject has an active systemic or cutaneous infection or inflammation (e.g., septicemia at the time of the procedure).
• Subject has systemic hypertension unresponsive to treatment (>180mmHg systolic and >110mm diastolic).
• Subject has significant bleeding coagulopathy or platelet disorder, (INR> 2.0), including known thrombocytopenia (platelet count <100,000/µL), thrombasthenia, Von Willebrand's disease, Factor V deficiency, or anemia (hemoglobin <10 g/dL, or hematocrit <30%).
• Subject presents with chronic renal insufficiency (creatinine ≥3.0mg/dl).
• Subject presents with hemodynamic instability or is in need of emergent surgery or emergent procedure.
• Subject presents with ST elevation myocardial infarction.
• Subject presents with unstable angina or non-ST elevation myocardial infarction and has troponin level > 3 X upper limit of normal. There must be at least one troponin level drawn > 6 hours after onset of chest pain.
• Subject has received low molecular weight heparin < 8 hours before vascular access, glycoprotein IIb/IIIa inhibitor < 24 hours before vascular access, unfractionated heparin by infusion < 1 hour before vascular access, or parenteral heparin at anticoagulant dose (as opposed to DVT prophylaxis)< 6 hours before vascular access.
• Subjects who are clinically obese, defined as BMI >40.
• Subject has received femoral artery Vessel Closure Implant (VCI) (suture or staple) at the target access site.
• Subject has received femoral artery VCI (collagen/PEG/PGA) at the target access site within 90 days of AXERA procedure.
• Subject is unable to routinely walk at least 20 feet without assistance (e.g., requires a walker or wheelchair to mobilize, is leg amputee or has known paralysis) or unable to ambulate within 2 hours post procedure.
• Subject has had prior vascular surgery or vascular grafts at the target femoral artery access site.
• Subject has had a previous target femoral artery complication from angiography (such as pseudoaneurysm, Arteriovenous (AV) fistula, dissection), small CFA, abnormal, absent or weak distal ipsilateral pulse, or presenting with clinically significant peripheral vascular disease in the vicinity of the puncture.
• Subject has a high puncture (i.e. above the inferior reflection of the inferior epigastric artery).
• Subject has antegrade puncture.
• Subject has a stent in the ipsilateral common femoral artery.
• Subject is currently participating in an investigational drug or another device study that clinically interferes with the current study endpoints.

Where it is running

• Heart Center Research, LLC — Huntsville, Alabama, United States
• Arkansas Heart Hospital — Little Rock, Arkansas, United States
• Scripps Green — La Jolla, California, United States
• Loma Linda University Health — Loma Linda, California, United States
• Mercy Heart and Vascular Institute — Sacramento, California, United States
• St. Joseph's Medical Center — Stockton, California, United States
• Christiana Care — Newark, Delaware, United States
• Medical Center of Central Georgia — Macon, Georgia, United States
• Opelousas General Health System — Opelousas, Louisiana, United States
• Sinai Hospital — Baltimore, Maryland, United States
• Hattiesburg Clinic — Hattiesburg, Mississippi, United States
• Northern Mississippi Medical Center — Tupelo, Mississippi, United States
• St. Rose Dominican — Las Vegas, Nevada, United States
• St. John Medical Center — Tulsa, Oklahoma, United States
• AnMed Health — Anderson, South Carolina, United States
• Lexington Medical Center — West Columbia, South Carolina, United States
• Franciscan Research Center — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.